Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70102 ↗At a glance
Übersichtsarbeit in Chemical Biology & Drug Design, 2025. Written by Yifan Wang and 7 co-authors. Institution: College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi Province, China. Major MEDLINE topics: Isocitrate Dehydrogenase, Drug Resistance, Neoplasm. Cited 6 times so far (Crossref); 78 references. Funded by: National Natural Science Foundation of China, Natural Science Foundation of Shaanxi Province, Sci-Tech Innovation Talent System Construction Program of Shaanxi University of Chinese Medicine.
Abstract (original language)
Isocitrate dehydrogenase 1 (IDH1) is a pivotal enzyme in cellular energy metabolism, playing a crucial role in the conversion of isocitrate into α‐ketoglutarate (α‐KG). When IDH1 undergoes mutation, it catalyzes the conversion of α‐KG into the oncogenic metabolite 2‐hydroxyglutarate (2‐HG). Subsequently, 2‐HG competitively suppresses a range of α‐KG‐dependent dioxygenase activities, ultimately leading to hypermethylation of DNA or histones, which in turn causes the occurrence of various malignant tumors, including acute myeloid leukemia (AML), glioma, and chondrosarcoma. Currently, the FDA has granted approval for the use of the small molecule inhibitor Ivosidenib (AG‐120) in the treatment of IDH1‐mutated AML and cholangiocarcinoma. Although AG‐120 has benefited patients clinically, drug resistance has gradually emerged and has become a major problem in the treatment of mutant IDH1 (mIDH1) diseases. In this review, we highlighted the function of IDH1 mutations in cancer treatment and described detailed resistance mechanisms in terms of IDH1‐specific mutation sites. Representative mIDH1 inhibitors and their binding modes were also discussed. In particular, we summarized seven strategies to overcome drug resistance, which provide a basis for understanding the mechanism of drug resistance for IDH1 mutations and exploring guidance to overcome drug resistance.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, Shaanxi Province, China.
- Gansu Corps Hospital of CAPF, Lanzhou, Gansu, China.
ORCID profiles: Yuwei Wang
Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Shaanxi Province
- Sci-Tech Innovation Talent System Construction Program of Shaanxi University of Chinese Medicine
- Xianyang Innovation Team of Innovation Capability Support Program
- CAPF Self-Help Research and Innovation
- CAPF High-level Science and Technology Talent Development
Cite
APA
Wang, Y., Bai, H., Wang, A., Zhao, J., Guo, H., Tang, Y., Wang, Y., & Xie, Q. (2025). Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70102
Vancouver
Wang Y, Bai H, Wang A, Zhao J, Guo H, Tang Y, et al. Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70102
BibTeX
@article{Wang2025,
author = {Wang, Yifan and Bai, Hailong and Wang, Aixin and Zhao, Jun and Guo, Hui and Tang, Yuping and Wang, Yuwei and Xie, Qinjian},
title = {Reviewing the IDH1 Mutation‐Mediated Mechanism of Drug Resistance and Revisiting Its Overcoming Strategies},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70102}
}
EUVIMED